StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI)
StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note issued to investors on Monday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright boosted their target price on shares of CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy […]
More Stories
ProPhase Labs Receives Notice from NASDAQ Regarding Minimum Bid Price Requirement On December 26, 2024, ProPhase Labs, Inc. (NASDAQ: PRPH) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC, indicating that the bid
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
2024 ‘one of the worst years in history for children in conflict’
The impact of armed conflicts on children around the world reached devastating and likely record levels in 2024, according to...
Anglo American plc (OTCMKTS:NGLOY) Sees Significant Drop in Short Interest
Anglo American plc (OTCMKTS:NGLOY – Get Free Report) was the target of a significant decrease in short interest during the...
Landis+Gyr Group AG (OTCMKTS:LGYRF) Short Interest Update
Landis+Gyr Group AG (OTCMKTS:LGYRF – Get Free Report) was the target of a significant decrease in short interest in the...
Triumph Gold (CVE:TIG) Trading Up 35.3% – Still a Buy?
Triumph Gold Corp. (CVE:TIG – Get Free Report) shot up 35.3% on Friday . The company traded as high as...
Analyzing XChange TEC.INC (NASDAQ:XHG) & Invitation Homes (NYSE:INVH)
XChange TEC.INC (NASDAQ:XHG – Get Free Report) and Invitation Homes (NYSE:INVH – Get Free Report) are both business services companies,...